“Design and Rationale of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)”, J of Skin, vol. 2, no. S1, p. S51, Feb. 2018, doi: 10.25251/skin.2.supp.51.